Synthego raises $110M series C to scale up CRISPR research products

Synthego Corp. (Redwood City, Calif.) raised a $110 million series C round to grow its CRISPR-based product line for researchers. Founders Fund led the round, which was also backed by fellow existing investors 8VC and Menlo Ventures.

Synthego markets CRISPR-engineered cells and CRISPR editing kits for experimental applications such as cell and gene therapies. Paul Dabrowski, Synthego's CEO, told BioCentury the company may extend its pipeline into new areas including disease models and clinical-grade materials for therapeutics developers. He said Synthego also aims to build out its capacity and improve its CRISPR engineering to make it a fully predictable tool...